Zai Lab
Mona Qureshi has extensive experience in clinical operations, starting in 2008 as a Research Data Coordinator at Boston Children's Hospital. From 2010 to 2015, they worked as a Clinical Research Manager at the Wyss Institute for Biologically Inspired Engineering. Following that, they joined Gilead Sciences as a Clinical Trials Manager specializing in oncology from 2015 to 2017. Mona then transitioned to Five Prime Therapeutics, Inc., where they held the positions of Senior Clinical Trials Manager and Clinical Program Manager between 2017 and 2019. Afterward, they joined Terns Pharmaceuticals as an Associate Director of Clinical Operations from 2019 to 2021. Currently, Mona is working at Zai Lab as an Associate Director of Clinical Operations since 2021 and has continued to progress to the role of Director of Clinical Operations starting from April 2023.
Mona Qureshi holds a Bachelor's Degree in Human Physiology from Boston University. In 2011, they obtained the Certified Clinical Research Professional (CCRP) certification from SoCRA.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.